Updated: January 25, 2026
Somatropin Shortage: What Providers and Prescribers Need to Know in 2026
Author
Peter Daggett
ChatGPT
Claude
Gemini
Overview
A clinical guide for providers managing patients on somatropin during the ongoing shortage: brand status, prescribing alternatives, PA strategies, and patient communication.
Is Somatropin in stock near you?
Based on 67 real pharmacy checks · 1 patients helped
Verified 26m ago
The somatropin (recombinant human growth hormone) shortage that began in November 2022 has fundamentally reshaped the growth hormone prescribing landscape. For clinicians managing patients on growth hormone therapy — pediatric endocrinologists, adult endocrinologists, PCPs with growth hormone patients, and NPs/PAs — staying current on brand availability, discontinued products, and alternative options is now an essential part of clinical practice.
This clinical summary covers what prescribers need to know in 2026 — from current brand status to alternative prescribing pathways and patient support resources.
Current Somatropin Brand Status (2026)
The following represents the current commercially available landscape for daily somatropin products in the U.S.:
Norditropin FlexPro (Novo Nordisk) — Available in 5 mg/1.5 mL, 10 mg/1.5 mL, 15 mg/1.5 mL pens. Most consistently stocked brand as of 2026. The 30 mg/3 mL size was discontinued in late 2025.
Genotropin (Pfizer) — Available; intermittent constraints persist. Pfizer increased production to 3.5x 2022 levels in 2023.
Omnitrope (Sandoz/Novartis) — Generally available; often lower cost; patient assistance programs available through Novartis.
Zomacton, Saizen — Limited specialty pharmacy distribution; check availability before prescribing.
Serostim (EMD Serono) — Indicated for HIV-associated wasting; generally available through specialty networks.
Zorbtive (EMD Serono) — Indicated for short bowel syndrome.
Humatrope (Eli Lilly) — DISCONTINUED. No longer commercially available. All patients must be transitioned.
Nutropin AQ NuSpin (Genentech) — DISCONTINUED December 2024. All patients must be transitioned.
Check live stock now.
Once-Weekly Alternatives: Clinical Overview
Three once-weekly long-acting growth hormone (LAGH) products are FDA-approved and currently available. These represent important alternatives for patients whose daily somatropin brand is unavailable, and may offer adherence advantages:
Sogroya (somapacitan-beco, Novo Nordisk) — Approved for adults with GHD and pediatric patients ≥2.5 years. Once-weekly SC injection. Comparable efficacy to daily somatropin in clinical trials.
Skytrofa (lonapegsomatropin-tcgd, Ascendis Pharma) — Approved for pediatric patients ≥1 year weighing ≥11.5 kg and adults with GHD. A 2025 NMA found statistically significantly higher annualized height velocity vs. daily somatropin (mean difference: 0.90 cm/year).
Ngenla (somatrogon-ghla, Pfizer) — Approved for pediatric patients ≥3 years. Produces higher IGF-1 SDS elevation than other products; careful monitoring recommended.
Prescribing Considerations When Transitioning Brands
When transitioning patients between daily somatropin brands or to a once-weekly product, consider the following:
Concentration differences: Different brands have different concentrations and pen devices. Verify dosing equivalence and educate patients on the new injection system.
Prior authorization: Most insurers (Cigna, UHC, Aetna) require PA for somatropin, and each brand typically requires its own authorization. Anticipate a new PA when switching brands.
Oral estrogen interactions: Women on oral estrogen replacement require higher somatropin doses; verify dosing is appropriate for the new brand.
IGF-1 monitoring: Obtain baseline IGF-1 before switching and recheck at 4–8 weeks to confirm dose equivalence.
Device training: All growth hormone devices differ. Ensure patients and caregivers receive training for any new pen or injection system.
Communicating With Patients About the Shortage
Proactive communication is essential. Consider reaching out to patients on Humatrope or Nutropin AQ NuSpin if you haven't already — these brands are no longer available and patients may not realize their prescription cannot be filled. Advise patients to:
Start refill searches 2–3 weeks before running out
Contact your office immediately if they cannot locate their brand
Use a pharmacy search service like medfinder to locate in-stock pharmacies near them
Help Patients Find Their Somatropin with medfinder
Providers can refer patients to medfinder for providers — a service that calls pharmacies on behalf of your patients to locate their growth hormone medication in stock. When a patient calls your office unable to fill their somatropin, directing them to medfinder can resolve the problem without requiring your staff to spend time on hold with specialty pharmacies.
Also read: how to help your patients find somatropin in stock and how to help patients save money on somatropin.
Real-time availability
Is Somatropin in stock near you?
Verified 26m ago
Based on 67 real pharmacy checks · 1 patients helped
Somatropin is in a shortage right now — Medfinder calls pharmacies near you to track down the ones that have it.
As of July 21, 2026, 2:01 AM ET, Somatropin is currently experiencing a shortage. Across 67 pharmacy checks Medfinder placed in the last 30 days, Somatropin was confirmed in stock 1% of the time.
- Pharmacy checks
- 67
- FDA status
- Not listed
- Updated
- 26m ago
Somatropin is not on the FDA's active shortage list. Medfinder's own pharmacy calls put real-time availability at 1% across 67 checks in the last 30 days. Availability varies by metro, with the most pharmacy activity recorded around Dallas, TX. These numbers are recomputed continuously from live pharmacy calls, so this page reflects current conditions rather than a static estimate.
Somatropin availability questions
Is Somatropin in stock right now?
As of July 21, 2026, 2:01 AM ET, Somatropin was confirmed in stock at 1% of 67 pharmacies Medfinder checked in the last 30 days. Availability changes daily, so we re-check in real time when you search.
How does Medfinder help me find Somatropin?
Medfinder calls pharmacies in your area to verify whether Somatropin and your specific dose are in stock, then sends you the pharmacy name, address, and phone number.
Need Somatropin? We'll find the pharmacy that has it.
Sources: FDA Drug Shortages + Medfinder pharmacy data · Methodology · Full Somatropin data
Frequently Asked Questions
Humatrope has been discontinued and is no longer available. Patients should be transitioned to an available daily somatropin brand (Norditropin, Genotropin, Omnitrope) or a once-weekly product (Sogroya, Skytrofa, Ngenla) if clinically appropriate. A new prescription and likely a new prior authorization will be required. Counsel patients on the new injection device.
Yes, in most cases. Major commercial payers including Cigna, UnitedHealthcare, and Aetna require prior authorization for each specific somatropin product. A brand switch typically requires a new PA. Prior auths for ongoing GHD therapy are generally approved for 12-month periods. Contact the payer's specialty pharmacy PA line to expedite for shortage-related switches.
Yes, based on available clinical evidence. Once-weekly products (Sogroya, Skytrofa, Ngenla) have demonstrated comparable or, in the case of Skytrofa, potentially superior growth outcomes vs. daily somatropin in clinical trials for pediatric GHD. Review each patient's specific diagnosis, age, and insurance formulary before switching. Monitoring IGF-1 after transition is recommended.
Yes. After any brand switch, recheck IGF-1 at 4–8 weeks to confirm dose equivalence and appropriate therapeutic response. This is especially important when switching between formulations with different concentrations or dosing schedules (daily vs. weekly). Adjust dose as needed based on IGF-1 results, clinical response, and adverse effects.
Some payers (including Cigna) require that somatropin be prescribed by or in consultation with an endocrinologist for specific indications. Review your payer-specific PA criteria carefully. For complex cases such as adult GHD after childhood treatment or cranial irradiation, endocrinology involvement is typically required for coverage approval.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Somatropin also looked for:
More about Somatropin
Why Is Somatropin So Hard to Find? [Explained for 2026]
How to Find Somatropin in Stock Near You (Tools + Tips)
Alternatives to Somatropin If You Can't Fill Your Prescription
Somatropin Shortage Update: What Patients Need to Know in 2026
How to Help Your Patients Find Somatropin in Stock: A Provider's Guide
How to Save Money on Somatropin in 2026: Coupons, Discounts, and Patient Assistance
38,004 have already found their meds with Medfinder.
Start your search today.
Your information is private and never shared.